Abstract: Direct ink write (DIW) printing of reactive resins presents a unique challenge due to the time-dependent nature of the rheological and chemical properties of the ink. As a result, careful print optimization or process control is important to obtain consistent, high quality prints. The present invention uses a flow-through characterization cell for in situ chemical monitoring of a resin ink during DIW printing. Additionally, in-line extrusion force monitoring can be combined with off-line post inspection using machine vision. By combining in-line spectroscopy and force monitoring, it is possible to follow reaction kinetics (for example, curing of a reactive resin) and viscosity changes during printing, which can be used for a closed-loop process control. Additionally, the capability of machine vision to automatically identify and quantify print artifacts can be incorporated on the printing line to enable real-time, AI-assisted quality control of the printed products.

Abstract: Direct ink write (DIW) printing of reactive resins presents a unique challenge due to the time-dependent nature of the rheological and chemical properties of the ink. As a result, careful print optimization or process control is important to obtain consistent, high quality prints. The present invention uses a flow-through characterization cell for in situ chemical monitoring of a resin ink during DIW printing. Additionally, in-line extrusion force monitoring can be combined with off-line post inspection using machine vision. By combining in-line spectroscopy and force monitoring, it is possible to follow reaction kinetics (for example, curing of a reactive resin) and viscosity changes during printing, which can be used for a closed-loop process control. Additionally, the capability of machine vision to automatically identify and quantify print artifacts can be incorporated on the printing line to enable real-time, AI-assisted quality control of the printed products.

Abstract: An assembly is provided for an aircraft propulsion system. This assembly includes a nacelle inner structure and a deflection limiter. The nacelle inner structure includes an internal compartment and a cowl. The internal compartment is configured to house a core of a gas turbine engine. The cowl is configured to form an outer radial periphery of the internal compartment. The cowl is also configured to form an outer radial periphery of a compartment exhaust to the internal compartment at an aft end of the cowl. The deflection limiter is attached to the cowl. The deflection limiter is configured to limit radial outward movement of the cowl.

Abstract: An assembly is provided for an aircraft propulsion system. The assembly includes a fixed structure, an inner cowl door and an outer cowl door. The inner cowl door is pivotally connected to the fixed structure. The outer cowl door is pivotally connected to the fixed structure. The outer cowl door is radially outboard of and overlaps the inner cowl door. The linkage extends between and is movably connected to the inner cowl door and the outer cowl door.

Abstract: Pin latch assemblies and cam latch assemblies are disclosed. A pin latch assembly is provided comprising a pin housing at least partially enclosing a pin, an actuating device coupled to the pin, and a retaining feature comprising an aperture.

Abstract: An assembly is provided for an aircraft propulsion system. The assembly includes a fixed structure, an inner cowl door and an outer cowl door. The inner cowl door is pivotally connected to the fixed structure. The outer cowl door is pivotally connected to the fixed structure. The outer cowl door is radially outboard of and overlaps the inner cowl door. The linkage extends between and is movably connected to the inner cowl door and the outer cowl door.

Abstract: An assembly is provided for an aircraft propulsion system. This assembly includes a nacelle inner structure and a deflection limiter. The nacelle inner structure includes an internal compartment and a cowl. The internal compartment is configured to house a core of a gas turbine engine. The cowl is configured to form an outer radial periphery of the internal compartment. The cowl is also configured to form an outer radial periphery of a compartment exhaust to the internal compartment at an aft end of the cowl. The deflection limiter is attached to the cowl. The deflection limiter is configured to limit radial outward movement of the cowl.

Abstract: Pin latch assemblies and cam latch assemblies are disclosed. A pin latch assembly is provided comprising a pin housing at least partially enclosing a pin, an actuating device coupled to the pin, and a retaining feature comprising an aperture.

Abstract: Pin latch assemblies and cam latch assemblies are disclosed. A pin latch assembly is provided comprising a pin housing at least partially enclosing a pin, an actuating device coupled to the pin, and a retaining feature comprising an aperture.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.

Abstract: Pin latch assemblies and cam latch assemblies are disclosed. A pin latch assembly is provided comprising a pin housing at least partially enclosing a pin, an actuating device coupled to the pin, and a retaining feature comprising an aperture.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.

Abstract: The present invention relates to compounds of formula (I), wherein R1 is heteroaryl or heterocyclyl, optionally substituted; R2 is C1-4alkyl, heterocyclyl, C1-4alkylaryl, C1-4alkylheteroaryl, carbocyclyl, C1-4alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R3 is hydrogen or C1-4alkyl, or R2 and R3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.

Abstract: The present invention relates to compounds of formula (I), wherein R1 is heteroaryl or heterocyclyl, optionally substituted; R2 is C1-4alkyl, heterocyclyl, C1-4alkylaryl, C1-4alkylheteroaryl, carbocyclyl, C1-4alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R3 is hydrogen or C1-4alkyl, or R2 and R3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.

Abstract: The present invention relates to compounds of formula (I), wherein R1 is heteroaryl or heterocyclyl, optionally substituted; R2 is C1-4alkyl, heterocyclyl, C1-4alkylaryl, C1-4alkylheteroaryl, carbocyclyl, C1-4alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R3 is hydrogen or C1-4alkyl, or R2 and R3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.